ESR1 and breast cancer: This is the first trial to determine the feasibility, efficacy and tolerability of head to head neoadjuvant everolimus plus letrozole versus neoadjuvant FEC chemotherapy in treating postmenopausal women with ER-positive, HER2-negative breast cancer.